KTKay Thomas

Kay Thomas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kay Thomas has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hypertension and renal impairment in patients with cystinuria: findings from a specialist cystinuria centre

    by Francesca Kum, Kathie Wong, David Game, Matthew Bultitude, Kay Thomas

    Higher blood pressures (mean systolic difference 16.8 mmHg) when compared to matched individuals are already reported in patients with calcium urolithiasis. We present the prevalence of hypertension and renal impairment in patients with cystinuria from our specialist single centre. We analysed our prospective database of adult patients with cystinuria who attend our cystinuria service. This included details of the medical and operative management of their disease. Descriptive statistics were used to analyse and present the data. 120 patients were included with a median age of 40 (19–76) years, 66 were male (55%) and 54 were female (45%). 54/120 patients (45%) were taking medications to prevent stone formation. 78% (94/120) patients reported having undergone one or more stone-related procedure. 59% (55/94) of these having required at least one PCNL or open procedure during their lifetime. Prevalence of hypertension was 50.8% (61/120), and double in males compared to females (62.1% vs. 37.0%, P = 0.0063). Mean baseline creatinine was 88.2 (49–153) µmol/l and eGFR was 77.6 (32–127) ml/min/1.73 m2. When categorized by CKD stage, only 24.6% (27% vs. 21%, M vs. F) patients had normal renal function (being an eGFR > 89 ml/min/1.73 m2). 57.6% patients were CKD stage 2 and 17.8% CKD stage 3. Females had a slightly greater incidence of renal impairment. All patients who have previously undergone a nephrectomy (n = 10) or have a poorly functioning kidney (n = 19) have renal impairment (CKD stage 2 or 3). Incidence of hypertension in patients with cystinuria is 51%, with a male preponderance. Only 25% of patients with cystinuria have normal renal function. This highlights the long-term cardiovascular and renal risks that the metabolic effects of cystinuria pose, in addition to the challenges of managing recurrent urolithiasis in a young population.


  • Open Access

    Associating mutations causing cystinuria with disease severity with the aim of providing precision medicine

    by Henry J. Martell, Kathie A. Wong, Juan F. Martin, Ziyan Kassam, Kay Thomas, Mark N. Wass

    Cystinuria is an inherited disease that results in the formation of cystine stones in the kidney, which can have serious health complications. Two genes (SLC7A9 and SLC3A1) that form an amino acid transporter are known to be responsible for the disease. Variants that cause the disease disrupt amino acid transport across the cell membrane, leading to the build-up of relatively insoluble cystine, resulting in formation of stones. Assessing the effects of each mutation is critical in order to provide tailored treatment options for patients. We used various computational methods to assess the effects of cystinuria associated mutations, utilising information on protein function, evolutionary conservation and natural population variation of the two genes. We also analysed the ability of some methods to predict the phenotypes of individuals with cystinuria, based on their genotypes, and compared this to clinical data. Using a literature search, we collated a set of 94 SLC3A1 and 58 SLC7A9 point mutations known to be associated with cystinuria. There are differences in sequence location, evolutionary conservation, allele frequency, and predicted effect on protein function between these mutations and other genetic variants of the same genes that occur in a large population. Structural analysis considered how these mutations might lead to cystinuria. For SLC7A9, many mutations swap hydrophobic amino acids for charged amino acids or vice versa, while others affect known functional sites. For SLC3A1, functional information is currently insufficient to make confident predictions but mutations often result in the loss of hydrogen bonds and largely appear to affect protein stability. Finally, we showed that computational predictions of mutation severity were significantly correlated with the disease phenotypes of patients from a clinical study, despite different methods disagreeing for some of their predictions. The results of this study are promising and highlight the areas of research which must now be pursued to better understand how mutations in SLC3A1 and SLC7A9 cause cystinuria. The application of our approach to a larger data set is essential, but we have shown that computational methods could play an important role in designing more effective personalised treatment options for patients with cystinuria.


  • The genetic diversity of cystinuria in a UK population of patients

    by Kathie A. Wong, Rachael Mein, Mark Wass, Frances Flinter, Caroline Pardy, Matthew Bultitude, Kay Thomas

    Objective: To examine the genetic mutations in the first UK cohort of patients with cystinuria with preliminary genotype/phenotype correlation. Patients and Methods: DNA sequencing and multiplex ligation‐dependent probe amplification ( MLPA ) were used to identify the mutations in 74 patients in a specialist cystinuria clinic in the UK . Patients with type A cystinuria were classified into two groups: Group M patients had at least one missense mutation and Group N patients had two alleles of all other types of mutations including frameshift, splice site, nonsense, deletions and duplications. The levels of urinary dibasic amino acids, age at presentation of disease, number of stone episodes and interventions were compared between patients in the two groups using the Mann–Whitney U ‐test. Results: In all, 41 patients had type A cystinuria, including one patient with a variant of unknown significance and 23 patients had type B cystinuria, including six patients with variants of unknown significance. One patient had three sequence variants in SLC 7A9; however, two are of unknown significance. Three patients had type AB cystinuria. Three had a single mutation in SLC 7A9. No identified mutations were found in three patients in either gene. There were a total of 88 mutations in SLC 3A1 and 55 mutations in SLC 7A9. There were 23 pathogenic mutations identified in our UK cohort of patients not previously published. In patients with type A cystinuria, the presence of a missense mutation correlated to lower levels of urinary lysine (mean [ se ] 611.9 [22.65] vs 752.3 [46.39] millimoles per mole of creatinine [m m / MC ]; P =0.02), arginine (194.8 [24.83] vs 397.7 [15.32] m m / MC ; P P =0.02). There was no difference in the levels of urinary cystine (182.1 [8.89] vs 207.2 [19.23] m m / MC ; P =0.23). Conclusions: We have characterised the genetic diversity of cystinuria in a UK population including 23 pathogenic mutations not previously published. Patients with at least one missense mutation in SLC 3A1 had significantly lower levels of lysine, arginine, and ornithine but not cystine than patients with all other combinations of mutations.


  • Outpatient laser ablation of non‐muscle‐invasive bladder cancer: is it safe, tolerable and cost‐effective?

    by Kathie A. Wong, Grace Zisengwe, Thanos Athanasiou, Tim O'BRien, Kay Thomas

    Objectives: To evaluate the safety, tolerability and effectiveness of outpatient (office‐based) laser ablation ( OLA ), with local anaesthetic, for non‐muscle‐invasive bladder cancer ( NMIBC ) in an elderly population with and without photodynamic diagnosis ( PDD ). To compare the cost‐effectiveness of OLA of NMIBC with that of inpatient cystodiathermy ( IC ). Patients and Methods: We conducted a prospective cohort study of patients with NMIBC treated with OLA by one consultant surgeon between M arch 2008 and J uly 2011 A subgroup of patients had PDD before undergoing OLA . Safety and effectiveness were determined by complications (In the immediate post operative period, at three days and at three months), patient tolerability (visual analogue score) and recurrence rates. The long‐term costs and cost‐effectiveness of OLA and IC of NMIBC were evaluated using M arkov modeling. Results: A total of 74 OLA procedures (44 white‐light, 30 PDD ) were carried out in 54 patients. The mean (range) patient age was 77 (52–95) years. More than half of the patients had more than three comorbidities. Previous tumour histology ranged from G1pTa to T 3. One patient had haematuria for 1 week which settled spontaneously and did not require hospital admission. There were no other complications. The procedure was well tolerated with pain scores of 0–2/10. Additional lesions were found in 21% of patients using PDD that were not found using white light. At 3 months, the percentage of patients who had recurrence after OLA with white light and OLA with PDD were 10.6 and 4.3%, respectively. At 1 year, 65.1% and 46.9% of patients had recurrence. The cost of OLA was found to be much lower than that of IC (£538 vs £1474), even with the addition of PDD (£912 vs £1844). Over the course of a patient's lifetime, OLA was more clinically effective, measured in quality‐adjusted life‐years ( QALY ), than IC (0.147 [ sd 0.059]) and less costly (£2576.42 [ sd £7293.07]). At a cost‐effectiveness threshold of £30 000/ QALY , as set by the N ational I nstitute for H ealth and C are E xcellence, there was an 82% probability that OLA was cost‐effective. Conclusions: This is the first study to demonstrate the long‐term cost‐effectiveness of OLA of NMIBC . The results support the use of OLA for the treatment of NMIBC , especially in the elderly.


  • Top Cited Papers

    The Guy's Stone Score—Grading the Complexity of Percutaneous Nephrolithotomy Procedures

    by Kay Thomas, Naomi C. Smith, Nicholas Hegarty, Jonathan M. Glass


  • WHY DON’T MERCEDES BENZ PUBLISH RANDOMIZED TRIALS?

    by Timothy O’bRien, Richard Viney, Alan Doherty, Kay Thomas


  • BLUE‐SKY THINKING ABOUT BLUE‐LIGHT CYSTOSCOPY

    by Kay Thomas, Timothy O’bRien